What NeuroPace (NPCE) Said on Its Q3 Earnings Call

NeuroPace (NPCE) reduced its 2026 revenue guidance to $91M-$92M from $99.5M-$101.5M, citing delays at large accounts. Q4 procedure volumes show recovery signs. Adjusted gross margin forecast raised to 83%-83.5%, while operating expenses lowered to $85M-$86M. 2027 RNS revenue growth expected at 15%. FDA submissions for IGE and Remote Care feature are planned.

Original reporting
Published Nov 13, 2026, 4:14 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 4:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
What NeuroPace (NPCE) Said on Its Q3 Earnings Call — source image
Decision brief

The 30-second read

$NPCEBearishMed
01

Why it matters

The guidance cut is the primary market‑moving element; other operational updates are secondary.

02

Market read

Guidance reduction is a fresh, material fact for investors; it likely triggers a sell‑side reaction.

03

What to watch

Potential upside from upcoming FDA submissions for IGE indication and Remote Care feature could mitigate revenue concerns.

Relevance 7/10Novelty 7/10Timing: post-market after earnings call

Background

NeuroPace reported Q3 results, improved margins, and provided updated 2026 guidance while outlining FDA submission plans for new indications.

Company-level read

Ticker impact

$NPCEBearishHigh confidence
Context

NeuroPace cut its 2026 revenue guidance to $91‑$92M, down from $99.5‑$101.5M, and lowered operating expense outlook.

Expected impact

likely downside as market prices in lower revenue expectations

Evidence & confidence

Revenue guidance is a material metric; the cut is a fresh disclosure that directly affects valuation.

Market effects

May weigh on med‑tech and neuro‑stimulation peers as demand outlook softens.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact beyond niche neuro‑tech segment.

Counterpoint

If the guidance cut reflects temporary delays rather than long‑term demand, the stock could rebound on a short‑term oversell.

Key entities

  • NeuroPace, Inc.

    Medical technology firm developing the RNS System for drug‑resistant epilepsy.

Related articles

$NPCEHigh

Why is NeuroPace stock plummeting 40% today?

NeuroPace (NPCE) stock fell 38.3% to $7.42 after reporting Q3 2026 revenue of $23.1M, missing estimates of $27.1M. The company cut its full-year 2026 revenue outlook to $91–92M from $99.5–101.5M, citing sales force disruptions. Leerink downgraded NPCE to Market Perform with a $7 target, while KeyBanc reduced its target to $14. Insider selling and a rate-sensitive macro environment added to the decline.

$NPCEMed

NeuroPace (NPCE) Q3 2026 Earnings Call Transcript

NeuroPace reported Q3 2026 revenue of $23.1M, missing expectations. CEO Joel Becker attributed the shortfall to transient issues, including account-specific operational challenges and sales team transitions. The company revised full-year revenue guidance to $91M-$92M and expects 15% core RNS revenue growth in 2027, accelerating to 20% by year-end. CMS increased the hospital outpatient payment rate for RNS replacement procedures by 11% for 2027.

$NPCEMed

NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance

NeuroPace Inc (NPCE) filed an SEC Form 8-K — Results of Operations and Financial Condition. NeuroPace Reports Third Quarter 2026 Financial Results and Provides Revised Full Year Guidance Q3 2026 total revenue of $23.1 million, including $22.9 million in RNS revenue representing 1% growth Revises full year 2026 revenue guidance to $91 million to $92 million; focused on i